General Information of Drug Therapeutic Target (DTT) (ID: TTRMIZ7)

DTT Name Peroxisome proliferator-activated receptor (PPAR)
Gene Name PPAR
DTT Type
Clinical trial target
[1]
UniProt ID
PPARA_HUMAN ; PPARD_HUMAN ; PPARG_HUMAN
TTD ID
T85042
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
KEGG Pathway
PPAR signaling pathway (hsa03320 )
cAMP signaling pathway (hsa04024 )
Adipocytokine signaling pathway (hsa04920 )
Glucagon signaling pathway (hsa04922 )
Insulin resistance (hsa04931 )
Non-alcoholic fatty liver disease (hsa04932 )
Alcoholic liver disease (hsa04936 )
Hepatitis C (hsa05160 )
Chemical carcinogenesis - receptor activation (hsa05207 )
Diabetic cardiomyopathy (hsa05415 )
Reactome Pathway
BMAL1 (R-HSA-1368108 )
PPARA activates gene expression (R-HSA-1989781 )
Transcriptional activation of mitochondrial biogenesis (R-HSA-2151201 )
Activation of gene expression by SREBF (SREBP) (R-HSA-2426168 )
Transcriptional regulation of white adipocyte differentiation (R-HSA-381340 )
Nuclear Receptor transcription pathway (R-HSA-383280 )
Regulation of lipid metabolism by PPARalpha (R-HSA-400206 )
Circadian Clock (R-HSA-400253 )
SUMOylation of intracellular receptors (R-HSA-4090294 )
Cytoprotection by HMOX1 (R-HSA-9707564 )
Heme signaling (R-HSA-9707616 )
RORA activates gene expression (R-HSA-1368082 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
3 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
A278 DMKXO9V Non-alcoholic steatohepatitis DB92.1 IND submitted [2]
IVA337 DMJV3AX Non-alcoholic steatohepatitis DB92.1 Phase 2 [1]
ABTL0812 DMM1W9R Pancreatic cancer 2C10 Phase 1/2 [3]
------------------------------------------------------------------------------------

References

1 Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Ann Rheum Dis. 2017 Nov;76(11):1931-1940.
2 Clinical pipeline report, company report or official report of Klus Pharma
3 The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells. Autophagy. 2021 Jun;17(6):1349-1366.